Breaking News Instant updates and real-time market news.

ADM

Archer Daniels

$40.82

-0.92 (-2.20%)

, NTR

Nutrien

$50.94

0.695 (1.38%)

08:01
07/17/19
07/17
08:01
07/17/19
08:01

Federal Reserve Bank of Kansas City to hold a symposium

2019 Agricultural Symposium will be held in Kansas City, MO on July 16-17.

ADM

Archer Daniels

$40.82

-0.92 (-2.20%)

NTR

Nutrien

$50.94

0.695 (1.38%)

  • 30

    Jul

  • 01

    Aug

  • 13

    Nov

ADM Archer Daniels
$40.82

-0.92 (-2.20%)

04/29/19
BARD
04/29/19
NO CHANGE
Target $48
BARD
Outperform
Archer Daniels price target lowered to $48 from $54 at Baird
Baird analyst Ben Kallo maintained an Outperform rating on Archer Daniels but lowered his price target to $48 from $54 following the Q1 earnings miss, saying a potential China trade deal remains the central focus, which he thinks he is key driver of earnings in the second half and that any resolution would be a positive catalyst. The analyst sees sequential improvement in Q2 and likes the set-up headed into a potential earnings inflection in the second half of the year.
04/29/19
MSCO
04/29/19
NO CHANGE
Target $47
MSCO
Equal Weight
Archer ethanol spin would be smart, but not 'game changer,' says Morgan Stanley
Morgan Stanley analyst Vincent Andrews said he expects a mixed response to Archer Daniels' results and outlook, stating that the disappointing headline results were largely due to challenging weather conditions that should be looked through. The company also announced further restructuring steps and a plan to break out its ethanol business, and potentially spin it off, which Andrews sees as a smart thing to do, but doesn't envision being "a game changer" for the stock. The company also plans to cut capex by 10%, which he thinks is "very sensible" given Andrews thinks returns on growth capex haven't ultimately been obvious as attractive. He maintains an Equal Weight rating on Archer Daniels shares with a $47 price target.
04/30/19
STFL
04/30/19
NO CHANGE
Target $56
STFL
Buy
African Swine Fever can provide boost to Archer Daniels, says Stifel
Stifel analyst Vincent Anderson noted that the USDA's most recent estimates are for an 18% decline in pig herds in 2019 due to African Swine Fever. He said the African Swine Fever outbreak is likely to drive a widening in soybean crush margins, explaining that the net effect of increasing ex-China demand for protein will be to increase soybean meal demand and decrease soybean demand. This expected widening of crush margins provides upside for Archer Daniels, which can also benefit from increased demand for its edible bean and pea non-animal proteins, said Anderson, who keeps a Buy rating and $56 price target on Archer Daniels shares.
07/12/19
BARD
07/12/19
NO CHANGE
BARD
Outperform
Darling Ingredients named a Fresh Pick at Baird
Baird analyst Ben Kallo named Darling Ingredients (DAR) as a Fresh Pick as he believes a rally in fat pricing should be a tailwind for the balance of the year. While he is more positive on Darling (DAR), Kallo said weather, trade, and African swine fever combine to make challenging ag environment more broadly and he is cautious in the near-term on Archer Daniels (ADM), Bunge (BG) and FMC Corporation (FMC). He keeps Outperform ratings on Darling and Archer and Neutral ratings on Bunge and FMC.
NTR Nutrien
$50.94

0.695 (1.38%)

01/08/19
BMOC
01/08/19
UPGRADE
BMOC
Outperform
Nutrien upgraded to Outperform at BMO Capital on portfolio advantages
As reported earlier, BMO Capital analyst Joel Jackson upgraded Nutrien to Outperform from Sector Perform while keeping his $55 price target. The analyst is positive on the Fertilizer sector as an "attractive shelter in broader materials space", having "lower economic sensitivity" and little likelihood of crop prices falling below challenged multi-year ranges. Jackson adds that Nutrien stands out in the group given its "safer diversified portfolio, stable Canadian investor base, lower commodity price sensitivity, strong balance sheet, and large amount of capital to redeploy."
03/19/19
SBSH
03/19/19
NO CHANGE
SBSH
Citi cuts Q1 fertilizer estimates on slow start to spring season
Citi analyst P.J. Juvekar cut his Q1 earnings for CF Industries (CF), Mosaic (MOS) and Nutrien (NTR) saying the start to the spring has been slow due in part to tough weather conditions in much of the Midwest. The cuts are driven by weather, not a change in fundamentals, Juvekar tells investors in a research note. He expects U.S. demand will pick up soon and thinks it is too early to "throw in the towel" for the spring season. Juvekar prefers shares of Nutrien, CF and Mosaic, in that order, and keeps Buy ratings on all three names.
03/25/19
COWN
03/25/19
NO CHANGE
COWN
Plantings report likely to create volatility for fertilizer stocks, says Cowen
Cowen analyst Charles Neivert said the annual Prospective Plantings report, due out on Friday, March 29 at noon, is likely to create some volatility around fertilizer shares as it represents the first important data point for the upcoming U.S. agricultural season. Grower economics favor corn over soybean acres as of now, said Neivert, who noted that expectations are for corn and wheat acres to rise, soybean acres to decline, and cotton acres to remain about flat. Agricultural chemicals stocks covered by the firm included CF Industries (CF), Nutrien (NTR), Intrepid Potash (IPI), CVR Partners (UAN) and Mosaic (MOS).
07/12/19
SBSH
07/12/19
DOWNGRADE
SBSH
Neutral
Chemours downgraded to Neutral from Buy at Citi
Citi analyst P.J. Juvekar downgraded Chemours (CC) to Neutral from Buy saying he's turned more cautious on ethylene and TiO2. With three new ethylene crackers in the second half of 2019 and falling raw materials, the risk to polyethylene prices is to the downside, Juvekar tells investors in a research note. He prefers "more defensive names with strong balance sheets," such as Linde plc (LIN), Sherwin-Williams (SHW) and Nutrien (NTR).

TODAY'S FREE FLY STORIES

SGEN

Seattle Genetics

$100.86

13.44 (15.37%)

07:24
10/22/19
10/22
07:24
10/22/19
07:24
Recommendations
Seattle Genetics analyst commentary  »

Seattle Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 07

    Dec

EMHTF

Emerald Health Therapeutics

$0.00

(0.00%)

07:24
10/22/19
10/22
07:24
10/22/19
07:24
Hot Stocks
Emerald Health Therapeutics expands cannabis products to Nova Scotia »

Emerald Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$183.73

7.49 (4.25%)

07:23
10/22/19
10/22
07:23
10/22/19
07:23
Recommendations
Vertex analyst commentary  »

Vertex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Mar

ORTX

Orchard Therapeutics

$12.09

0.1 (0.83%)

07:22
10/22/19
10/22
07:22
10/22/19
07:22
Hot Stocks
Orchard Therapeutics 'on track' to submit MAA for MLD in 1H20 »

Orchard remains on track…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

BABA

Alibaba

$173.57

4.39 (2.59%)

07:22
10/22/19
10/22
07:22
10/22/19
07:22
Recommendations
Alibaba analyst commentary  »

Daiwa expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 19

    Nov

ORTX

Orchard Therapeutics

$12.09

0.1 (0.83%)

07:21
10/22/19
10/22
07:21
10/22/19
07:21
Hot Stocks
Orchard Therapeutics presents data from OTL-200 in patients with MLD »

Orchard Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SWI

SolarWinds

$19.05

0.22 (1.17%)

07:20
10/22/19
10/22
07:20
10/22/19
07:20
Downgrade
SolarWinds rating change  »

SolarWinds downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CHTR

Charter

$438.01

-2.45 (-0.56%)

07:20
10/22/19
10/22
07:20
10/22/19
07:20
Recommendations
Charter analyst commentary  »

Charter price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

NVCN

Neovasc

$3.72

0.17 (4.79%)

07:18
10/22/19
10/22
07:18
10/22/19
07:18
Hot Stocks
Neovasc announces multiple presentations featuring Neovasc Reducer »

Neovasc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KDMN

Kadmon

$3.08

0.17 (5.84%)

07:17
10/22/19
10/22
07:17
10/22/19
07:17
Hot Stocks
Kadmon reports FDA approval of Clovique generic product »

Kadmon Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTU

Intuit

$262.05

-0.49 (-0.19%)

07:17
10/22/19
10/22
07:17
10/22/19
07:17
Downgrade
Intuit rating change  »

Intuit downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

QTRH

Quarterhill

$1.29

0.05 (4.03%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16
Hot Stocks
Quarterhill names David Cortens as interim CFO, succeeding Shaun McEwan »

Quarterhill announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCY

Oncolytics

$0.47

-0.0138 (-2.83%)

, PFE

Pfizer

$36.45

-0.01 (-0.03%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16
Hot Stocks
Oncolytics, PrECOG announce collaboration for Bracelet-1 study in metastatic BC »

Oncolytics Biotech (ONCY)…

ONCY

Oncolytics

$0.47

-0.0138 (-2.83%)

PFE

Pfizer

$36.45

-0.01 (-0.03%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Dec

KMT

Kennametal

$29.76

-0.97 (-3.16%)

07:16
10/22/19
10/22
07:16
10/22/19
07:16
Recommendations
Kennametal analyst commentary  »

Kennametal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 05

    Nov

  • 14

    Nov

ETON

Eton Pharmaceuticals

$5.66

-0.395 (-6.52%)

07:14
10/22/19
10/22
07:14
10/22/19
07:14
Hot Stocks
Eton Pharmaceuticals announces FDA approval of Biorphen injection »

Eton Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

WDAY

Workday

$154.10

-0.54 (-0.35%)

07:14
10/22/19
10/22
07:14
10/22/19
07:14
Upgrade
Workday rating change  »

Workday upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$118.56

1.23 (1.05%)

07:13
10/22/19
10/22
07:13
10/22/19
07:13
Hot Stocks
UPS announces retirement of COO Jim Barber »

UPS announced COO Jim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

IPG

Interpublic Group

$20.79

0.14 (0.68%)

07:11
10/22/19
10/22
07:11
10/22/19
07:11
Earnings
Interpublic Group 'on track' to deliver high end of 2%-3% organic growth in 2019 »

Consensus $8.65B. CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAPL

Apple

$240.49

4.2 (1.78%)

07:11
10/22/19
10/22
07:11
10/22/19
07:11
Recommendations
Apple analyst commentary  »

KeyBanc views near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

07:10
10/22/19
10/22
07:10
10/22/19
07:10
Hot Stocks
Procter & Gamble: Q1 operating profit margin increased 280 basis points »

Operating profit margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

PG

Procter & Gamble

$119.04

1.55 (1.32%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Hot Stocks
Procter & Gamble: Q1 reported gross margin increased 180 basis points »

Q1 Reported gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

VCYT

Veracyte

$26.18

1.52 (6.16%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Hot Stocks
Veracyte announces preliminary nasal swab test clinical data »

Veracyte announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Dec

PRVB

Provention Bio

$6.09

-0.48 (-7.31%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Hot Stocks
Provention Bio announces results from Phase 2a PRINCE clinical trial »

Provention Bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAN

Anaplan

$44.35

0.34 (0.77%)

07:09
10/22/19
10/22
07:09
10/22/19
07:09
Upgrade
Anaplan rating change  »

Anaplan upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPG

Interpublic Group

$20.79

0.14 (0.68%)

07:08
10/22/19
10/22
07:08
10/22/19
07:08
Earnings
Interpublic Group reports Q3 adjusted EPS 49c, consensus 47c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.